Related Experiment Video
Updated: Aug 10, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Novel Therapeutic Targets in Melanoma
Michaël Cerezo1, Stéphane Rocchi1
1INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Equipe 12, Bâtiment ARCHIMED, 151 Route de St Antoine de Ginestière, BP2 3194, CEDEX 3, 06204 Nice, France.
Melanoma, the deadliest skin cancer, resists therapies. New research explores novel therapeutic strategies to overcome melanoma treatment resistance and improve patient outcomes.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Melanoma is a highly aggressive skin cancer.
- It exhibits resistance to existing therapies, contributing to its high mortality rate.
Discussion:
- Current therapeutic strategies for melanoma face challenges due to acquired resistance.
- Understanding the mechanisms of resistance is crucial for developing effective treatments.
Key Insights:
- Melanoma's resistance necessitates the exploration of novel therapeutic targets.
- Investigating alternative treatment modalities is essential for improving patient survival rates.
Outlook:
- Future research should focus on innovative approaches to combat melanoma resistance.
- Developing next-generation therapies holds promise for overcoming treatment limitations in melanoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Mitogens and the Cell Cycle
Inhibition of Cdk Activity
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

